GREB1L divergent transcript (GREB1L-DT)

GREB1L divergent transcript (GREB1L-DT) refers to a genomic transcript identified in the region near or overlapping with the GREB1L gene, specifically transcribed in a direction divergent from GREB1L. According to gene annotation resources such as BioGPS, GREB1L-DT is listed as a transcript with accession numbers 101927496 (NCBI Gene) and ENSG00000265984 (Ensembl), and mapped to chromosome 18:21140441-21242796 (hg38)[5]. Current public resources provide minimal characterization—it is not a protein-coding gene, has no reported function, and is not classified as a classical drug target (e.g., receptor, enzyme, transporter, or transcription factor). There are no known biological functions, disease associations, drug interactions, or clinical biomarker data for GREB1L-DT. Most functional and disease-related information in the literature pertains to the neighboring protein-coding gene GREB1L, not GREB1L-DT[1][3][7]. Therefore, GREB1L-DT is best classified as an uncharacterized, likely non-coding RNA, with insufficient evidence to consider it a therapeutic target, or to ascribe clinical or biological roles. Note: There is a relevant issue with this target entry: - GREB1L-DT refers to a transcript with limited or no functional annotation, not a recognized therapeutic target, nor a well-characterized molecular entity in drug discovery or disease mechanisms. - Much published work and drug-related investigations concern GREB1L (the protein-coding gene), not GREB1L-DT. - As of now, GREB1L-DT should not be mistaken for GREB1L or used as a canonical target without further characterization[5][7].

Other names

GREB1L divergent transcriptGREB1L-DT